GI Surgery Pre-Operative Nutrition
The Effect of Pre-Operative Immunonutrition With "Impact Advanced Recovery (R)" on Patients Undergoing Major GI Cancer Surgery
1 other identifier
interventional
108
1 country
1
Brief Summary
Surgical patients are high risk for post operative infections. These post operative infections contribute to increased length of hospital stay, hospital costs and delay overall recovery time thus decreasing the quality of life. Studies have reported post operative complications ranging from 37% to 74%.1 The most costly complications include infectious complications after major Gastrointestinal (GI) surgery including wound infections, abdominal abscess, pneumonia, sepsis and anastomic leaks.2 Several studies have been conducted that show a significant reduction in infectious complications and average length of stay when treated with immunonutrition supplements.2-3 A review of similarly designed studies in a different patient population indicate that post-operative infections can be reduced by an average of 71% with immunonutrition. This study seeks to investigate the effect of Impact Advanced Recovery ® in improving surgical outcomes in patients receiving major gastrointestinal surgeries compared to a standard supplement at James A. Haley Veterans' Hospital. Providing Impact Advanced Recovery ® may decrease post-operative infectious complications, length of stay, and recovery time. Hypothesis
- 1.In patients receiving elective gastrointestinal surgery (esophageal, gastric, pancreatic or colon resections) there will be a significant decrease of at least 60% in post-operative infections as listed below for patients who consume 15 servings of Impact Advanced Recovery® pre-operatively compared to patients who consume 15 servings of a standard supplement.
- 2.In patients receiving elective gastrointestinal surgery (esophageal, gastric, pancreatic or colon resections) there will be a significant decrease in hospital and NPO days for patients who consume 15 servings of Impact Advanced Recovery ® pre-operatively.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Nov 2011
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2011
CompletedFirst Submitted
Initial submission to the registry
November 9, 2011
CompletedFirst Posted
Study publicly available on registry
November 16, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2016
CompletedFebruary 23, 2016
February 1, 2016
4.3 years
November 9, 2011
February 22, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Number of participants with post-op Infections
Determine the effectiveness of pre-operative supplementation with Impact Advanced Recovery ® on reducing the risk of developing complications during the 30 day post-operative period with decreased length of hospital stay, and time to resume an oral diet.
within 30 days post-operatively
Study Arms (2)
Impact Advance Recovery (R)
EXPERIMENTAL3 supplements per day for 5 days pre-operatively
Standard Supplement
ACTIVE COMPARATOR3 supplement per day for 5 days pre-operatively
Interventions
Eligibility Criteria
You may qualify if:
- Histologically documented neoplasm of the gastrointestinal tract.
- Planned major elective surgery including esophageal, gastric, pancreatic or colon resections.
You may not qualify if:
- Critically ill patients defined as any patient admitted to the intensive care unit (ICU) prior to elective surgery.
- Current use of steroids or other immunosuppressive medications.
- History of hospitalization for pulmonary, cardiac or renal disease in the 6 months prior to elective surgery.
- Patients who exhibit signs and symptoms of infection or sepsis including: elevated WBC above 10,000 cells/ml; temperature \> 37.7 C
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
James A. Haley VA Hospital
Tampa, Florida, 33612, United States
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- PARALLEL
- Sponsor Type
- FED
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Chief, Clinical Nutrition
Study Record Dates
First Submitted
November 9, 2011
First Posted
November 16, 2011
Study Start
November 1, 2011
Primary Completion
February 1, 2016
Study Completion
February 1, 2016
Last Updated
February 23, 2016
Record last verified: 2016-02